Endonovo Therapeutics (ENDV) 10-K 13 Apr 22 2021 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2021	Apr. 13, 2022	Jun. 30, 2021
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	000-55453
Entity Registrant Name	ENDONOVO THERAPEUTICS, INC.
Entity Central Index Key	0001528172
Entity Tax Identification Number	45-2552528
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	6320 Canoga Avenue
Entity Address, Address Line Two	15th Floor
Entity Address, City or Town	Woodland Hills
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91367
City Area Code	(800)
Local Phone Number	489-4774
Trading Symbol	ENDV
Title of 12(g) Security	Common stock, par value $0.0001
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 2,304,075
Entity Common Stock, Shares Outstanding		149,527,538
Documents Incorporated by Reference	None
ICFR Auditor Attestation Flag	false
Auditor Firm ID	468
Auditor Name	Rose, Snyder & Jacobs LLP
Auditor Location	Encino, CA

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current Assets:
Cash	$ 85,936	$ 13,420
Accounts receivable, net of allowance for doubtful accounts of $0	944	942
Prepaid expenses and other current assets	7,975	31,825
Total current assets	94,855	46,187
Property Plant and Equipment, net		1,580
Patents, net	1,912,356	2,559,268
Total assets	2,007,211	2,607,035
Current Liabilities
Accounts payable	658,463	700,932
Accrued interest	2,528,459	1,904,136
Deferred compensation	3,891,361	3,384,117
Notes payable, net of discounts of $75,800 as of December 31, 2021, and $201,157 as of December 31, 2020	7,055,030	6,491,039
Notes payable – former related party	126,100	143,000
Derivative liability	3,442,297	4,202,597
Total current liabilities	17,701,710	16,825,821
Acquisition payable	79,825	155,000
Total liabilities	17,781,535	16,980,821
Shareholders’ deficit
Preferred stock value
Common stock, $0.0001 par value; 2,500,000,000 shares authorized; and 74,498,761 and 24,536,689 shares issued and outstanding as of December 31, 2021, and December 31, 2020, respectively	7,449	2,453
Additional paid-in capital	40,663,187	38,963,827
Stock subscriptions	(1,570)	(1,570)
Accumulated deficit	(56,443,416)	(53,338,522)
Total shareholders’ deficit	(15,774,324)	(14,373,786)
Total liabilities and shareholders’ deficit	2,007,211	2,607,035
Super AA Super Voting Preferred Stock [Member]
Shareholders’ deficit
Preferred stock value	25	25
Series B Convertible Preferred Stock [Member]
Shareholders’ deficit
Preferred stock value	1	1
Series C Convertible Preferred Stock [Member]
Shareholders’ deficit
Preferred stock value
Series D Convertible Preferred Stock [Member]
Shareholders’ deficit
Preferred stock value

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Allowance for doubtful accounts receivable	$ 0	$ 0
Discounts on notes payable current	$ 75,800	$ 201,157
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	2,500,000,000	2,500,000,000
Common stock, shares issued	74,498,761	24,536,689
Common stock, shares outstanding	74,498,761	24,536,689
Super AA Super Voting Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	25,000	25,000
Preferred stock, shares outstanding	25,000	25,000
Series B Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	50,000	50,000
Preferred stock, shares issued	600	600
Preferred stock, shares outstanding	600	600
Series C Convertible Preferred Stock [Member]
Preferred stock, shares authorized	8,000	8,000
Preferred stock, shares issued	738	763
Preferred stock, shares outstanding	738	763
Series D Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	20,000	20,000
Preferred stock, shares issued	305	305
Preferred stock, shares outstanding	305	305

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Statement [Abstract]
Revenue	$ 73,105	$ 165,796
Cost of revenue	14,985	65,369
Gross profit	58,120	100,427
Operating expenses	2,284,667	3,012,625
Loss from operations	(2,226,547)	(2,912,198)
Other income (expense)
Change in fair value of derivative liability	41,057	5,607,213
Gain (loss) on extinguishment of debt	22,162	(555,430)
Other expense, net		(452,095)
Interest expense, net	(941,566)	(2,083,074)
Total other income (expense)	(878,347)	2,516,614
Loss before income taxes	(3,104,894)	(395,584)
Provision for income taxes
Net loss	$ (3,104,894)	$ (395,584)
Basic and diluted loss per share	$ (0.05)	$ (0.03)
Weighted average common share outstanding:
Basic and diluted	59,836,620	12,215,844

Consolidated Statement of Stock

Consolidated Statement of Stockholders Deficit - USD ($)	Preferred Stock [Member]Series AA Preferred Stock [Member]	Preferred Stock [Member]Series B Convertible Preferred Stock [Member]	Preferred Stock [Member]Series D Convertible Preferred Stock [Member]	Preferred Stock [Member]Series C Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Subscription Receivable [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2019	$ 25	$ 1			$ 118	$ 32,432,392	$ (1,570)	$ (52,934,786)	$ (20,503,820)
Beginning balance, shares at Dec. 31, 2019	25,000	600	255		1,189,204
Reclassification Preferred Series C						2,418,269			2,418,269
Reclassification Preferred Series C, shares				1,814
Shares issued for Preferred Series D						50,000			50,000
Shares issued for Preferred Series D, shares			50
Shares issued for conversion of notes payable and accrued interest					$ 1,456	3,337,653			3,339,109
Shares issued for conversion of notes payable and accrued interest, shares					14,557,343
Shares issued for conversion of Preferred Series C to common share					$ 276	(151)			125
Shares issued for conversion of Preferred Series C to common share, shares				(1,051)	2,754,822
Valuation of stock options issued for services						57,400			57,400
Shares issued for exchange of stock options					$ 150	164,850			165,000
Shares issued for exchange of stock options, shares					1,500,000
Shares issued as inducement to note holder					$ 85	79,055			79,140
Shares issued as inducement to note holder, shares					855,000
Common stock issued for services					$ 120	109,680			109,800
Common stock issued for Services, shares					1,206,398
Restricted shares issued as inducement to Series C					$ 6	8,146		(8,152)
Restricted shares issued as inducement to Series C, shares					58,428
Common stock issued with exchange of convertible notes					$ 41	58,814			58,855
Common stock issued with exchange of convertible notes, shares					409,000
Commitment shares					$ 78	97,842			97,920
Commitment shares, shares					771,926
Common Stock issued for cash					$ 123	99,877			100,000
Common stock issued for cash, shares					1,234,568
Beneficial conversion feature on convertible note						50,000			50,000
Net loss								(395,584)	(395,584)
Ending balance, value at Dec. 31, 2020	$ 25	$ 1			$ 2,453	38,963,827	(1,570)	(53,338,522)	(14,373,786)
Ending balance, shares at Dec. 31, 2020	25,000	600	305	763	24,536,689
Shares issued for conversion of notes payable and accrued interest					$ 2,746	1,115,244			$ 1,117,990
Shares issued for conversion of notes payable and accrued interest, shares					27,461,307				27,461,307
Shares issued for conversion of Preferred Series C to common share					$ 111	(111)
Shares issued for conversion of Preferred Series C to common share, shares				(25)	1,111,111
Common Stock issued for cash					$ 700	125,300			$ 126,000
Common stock issued for cash, shares					7,000,000				2,505,834
Net loss								(3,104,894)	$ (3,104,894)
Issuance of Commitment shares in connection with promissory notes					$ 787	221,905			222,692
Issuance of Commitment shares in connection with promissory notes, shares					7,868,668
Common Shares issued from debt settlement					$ 151	57,576			57,727
Common Shyaresissued from debt settlement, shares					1,515,152
Common Share issued as settlement of debt with former related part					$ 251	84,446			84,697
Common Share issued as settlement of debt with former related part, shares					2,505,834
Common Shares issued pursuant to consulting agreement					$ 250	95,000			95,250
Common Shares issued pursuant to consulting agreement, shares					2,500,000
Ending balance, value at Dec. 31, 2021	$ 25	$ 1			$ 7,449	$ 40,663,187	$ (1,570)	$ (56,443,416)	$ (15,774,324)
Ending balance, shares at Dec. 31, 2021	25,000	600	305	738	74,498,761

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating activities:
Net loss	$ (3,104,894)	$ (395,584)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization expense	648,492	651,247
Amortization of discount on Series C Preferred stock liability		248
Non-cash increase to convertible notes principal (included in interest expense)		452,095
Fair value of commitment shares issued with debt	70,970
Fair value of equity issued for services	95,250
Non-cash interest and fees		1,032,358
Stock compensation expense		456,519
Amortization of note discount and original issue discount	144,196	225,171
Change in fair value of derivative liability	(41,057)	(5,607,213)
Loss (gain) on extinguishment of debt	(22,162)	555,430
Changes in assets and liabilities:
Accounts receivable	(2)	21,800
Prepaid expenses and other current assets	23,850	(10,905)
Accounts payable	(42,470)	94,202
Accrued interest	733,999	830,298
Deferred compensation	507,244	952,744
Net cash used in operating activities	(986,584)	(741,590)
Investing activities:
Acquisition of property and equipment
Net cash used in investing activities
Financing activities:
Proceeds from the issuance of notes payable	950,000	608,117
Repayments on former related party advances	(16,900)	(22,000)
Proceeds from issuance of common stock and units	126,000	100,000
Proceeds from issuance of preferred shares		50,000
Net cash provided by financing activities	1,059,100	736,117
Net increase (decrease) in cash	72,516	(5,473)
Cash, beginning of year	13,420	18,893
Cash, end of year	85,936	13,420
Supplemental disclosure of cash flow information:
Cash paid for interest		25,747
Cash paid for income taxes
Non-Cash Investing and Financing Activities:
Conversion of notes payable and accrued interest to common stock	493,748	1,493,413
Conversion of Preferred C stock to common stock	33,333	1,400,934
Value of derivative liability from transfer to equity upon conversion of notes payable and accrued interest		1,879,398
Exchange of note and accrued interest to new convertible note		316,494
Issuance of common stock to Preferred C Stock inducement		8,152
Issuance of common stock to settle debt	$ 202,697

Nature of Business and Summary

Nature of Business and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business and Summary of Significant Accounting Policies	Note 1 - Nature of Business and Summary of Significant Accounting Policies Endonovo Therapeutics, Inc. (Endonovo or the “Company”) is an innovative biotechnology company that has developed a bio-electronic approach to regenerative medicine. Endonovo is a growth stage company whose stock is publicly traded (OTCQB: ENDV). The Company develops, manufactures, and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of inflammation on and in the human body. The Company’s non-invasive bioelectric medical devices are designed to target inflammation, cardiovascular diseases, chronic kidney disease, and central nervous system disorders (“CNS” disorders). Endonovo’s core mission is to transform the field of medicine by developing safe, wearable, non-invasive bioelectric medical devices that deliver the Company’s Electroceutical ® ® bioelectricity On January 22, 2014, Hanover Portfolio Acquisitions, Inc. (the “Company”) received written consents in lieu of a meeting of stockholders from holders of a majority of the shares of Common Stock representing in excess of 50% of the total issued and outstanding voting power Basis of Presentation and Principles of Consolidation The consolidated financial statements of the Company include the accounts of ETI, IP Resources International, Inc., Aviva Companies Corporation, and WeHealAnimals, Inc. All significant intercompany accounts and transactions are eliminated in consolidation. Going Concern These accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for a period following the date of these consolidated financial statements. The Company has recurring net losses, negative cash flows from operations and working capital deficits. The Company has raised approximately $ 1.1 Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Critical estimates include the value of shares issued for services, in connection with notes payable agreements, in connection with note extension agreements, and as repayment for outstanding debt, the useful lives of property and equipment, the valuation of the derivative liability, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates. Cash and cash equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Financial instruments that potentially subject us to a concentration of credit risk consist of cash and cash equivalents. Cash is deposited with what we believe are highly credited, quality institutions. The deposited cash may exceed Federal Deposit Insurance Corporation (“FDIC”) insured limits. At December 31, 2021, the Company does not hold any cash in excess of FDIC limits. Accounts Receivable The Company uses the specific identification method for recording the provision for doubtful accounts, which was $ 0 Property, plant, and equipment Property, plant, and equipment are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range between five seven years Impairment of Long-lived Assets The Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. If impairment is indicated, the asset is written down to its estimated fair value. Equity-Based Compensation The Company measures equity-based compensation cost at the grant date based on the fair value of the award and recognizes it as expense, net of forfeitures which are recognized as they occur, over the vesting or service period, as applicable, of the stock award using the straight-line method. The Company measured equity-based compensation using the Black-Scholes option valuation model using the following assumptions: Schedule of Measured Stock - Based Compensation For Years Ending December 31, 2021 2020 Expected term - 1.38 Exercise price $ - $ 0.15 Expected volatility - $ 23,110 Expected dividends - None Risk-free interest rate - 0.14 % Forfeitures - None Income Taxes The Company records a tax provision for the anticipated tax consequences of its reported results of operations. The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating losses and income tax credit carry-forward. Deferred tax assets and liabilities are measured using the currently enacted tax rates that apply to taxable income in effect for the years in which those tax assets are expected to be realized or settled. The Company records a valuation allowance to reduce deferred tax assets to the amount that is more likely than not to be realized. The Company has adopted ASC Topic 740, which clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. ASC Topic 740 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return, and also provides guidance on derecognition of tax benefits, classification on the balance sheet, interest and penalties, accounting in interim periods, disclosure and transition. The Company has determined that the adoption did not result in the recognition of any liability for unrecognized tax benefits and that there are no unrecognized tax benefits that would, if recognized, affect the Company’s effective tax rate. Net Loss per Share Basic net loss per share is calculated based on the net loss attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted net loss per common share assumes the conversion of all dilutive securities using the if-converted method and assumes the exercise or vesting of other dilutive securities, such as options, common shares issuable under convertible debt, warrants and restricted stock using the treasury stock method when dilutive. Research and Development Costs relating to the development of new products are expensed as research and development as incurred in accordance with FASB Accounting Standards Codification (“ASC”) 730-10, Research and Development 0 3,283 Fair Value of Financial Instruments Accounting guidance on fair value measurements and disclosures defines fair value, establishes a framework for measuring the fair value of assets and liabilities using a hierarchy system, and defines required disclosures. It clarifies that fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the market in which the reporting entity transacts business. The Company’s balance sheet contains derivative liability that is recorded at fair value on a recurring basis. The three-level valuation hierarchy for disclosure of fair value is as follows: Level 1: uses quoted market prices in active markets for identical assets or liabilities. Level 2: uses observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: uses unobservable inputs that are not corroborated by market data. The fair value of the Company’s recorded derivative liability is determined based on unobservable inputs that are not corroborated by market data, which require a Level 3 classification. A Black-Sholes option valuation model was used to determine the fair value. The Company records derivative liability on the condensed consolidated balance sheets at fair value with changes in fair value recorded in the condensed consolidated statements of operation. The following table presents balances of the liabilities with significant unobservable inputs (Level 3) as of December 31, 2021, and 2020: Schedule of Balances of Liabilities Measured at Fair Value Fair Value Measurements at December 31, 2021 Using Quoted Prices in Significant Significant Identical Observable Unobservable (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 3,442,297 $ 3,442,297 Total $ - $ - $ 3,442,297 $ 3,442,297 Fair Value Measurements at December 31, 2020 Using Quoted Prices in Significant Significant Identical Observable Unobservable (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 4,202,597 $ 4,202,597 Total $ - $ - $ 4,202,597 $ 4,202,597 The following table presents changes of the liabilities with significant unobservable inputs (Level 3) for the years ended December 31, 2021, and 2020: Schedule of Changes in the Liabilities with Significant Unobservable Inputs Derivative Liability Balance December 31, 2019 $ 10,599,690 Issuance of convertible debt 1,244,898 Settlements by debt extinguishment (1,857,356 ) Extinguishment following note exchange (177,422 ) Change in estimated fair value (5,607,213 ) Balance December 31, 2020 $ 4,202,597 Issuance of convertible debt - Settlement by debt Extinguishment (133,386 ) Settlements by debt conversion (585,857 ) Change in estimated fair value (41,057 ) Balance December 31, 2021 $ 3,442,297 Derivative Liability The Company issued Variable Debentures during the years ended December 31, 2021, and 2020, which contained variable conversion rates based on unknown future prices of the Company’s common stock. This resulted in a derivative liability. The Company measures the derivative liability using the Black-Scholes option valuation model using the following assumptions: Schedule of Variable Debentures Black-Scholes Valuation Assumptions For Years Ending December 31, 2021 2020 Expected term 1 4 1 6 Exercise price $ 0.01 0.03 $ 0.01 0.76 Expected volatility 177 206 110 249 Expected dividends None None Risk-free interest rate 0.06 0.39 0.03 1.54 Forfeitures None None The assumptions used in determining fair value represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment. As a result, if factors change, including changes in the market value of the Company’s common stock, managements’ assessment or significant fluctuations in the volatility of the trading market for the Company’s common stock, the Company’s fair value estimates could be materially different in the future. The Company computes the fair value of the derivative liability at each reporting period and the change in the fair value is recorded as non-cash expense or non-cash income. The key component in the value of the derivative liability is the Company’s stock price, which is subject to significant fluctuation and is not under its control, and the assessment of volatility. The resulting effect on net loss is therefore subject to significant fluctuation and will continue to be so until the Company’s Variable Debentures, which the convertible feature is associated with, are converted into common stock or paid in full with cash. Assuming all other fair value inputs remain constant, the Company will record non-cash expense when its stock price increases and non-cash income when its stock price decreases. Preferred Stock The Company elects to accrete the difference between the redemption value and carrying value of outstanding preferred stock over the period from the date of issuance to the earliest redemption date using the effective interest method. Recent Accounting Standard Updates In August 2020, the FASB issued ASU No. 2020-06 (“ASU 2020-06”) “Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity.” ASU 2020-06 simplifies the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models results in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. In addition, ASU 2020-06 amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. The Amendments also affects the diluted EPS calculation for instruments that may be settled in cash or shares and for convertible instruments. The amendments are effective for public entities excluding smaller reporting companies for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods. The Company adopted the new standard update on January 1, 2021, which did not result in a material impact on the Company’s consolidated results of operations, financial position, and cash flows.

Revenue Recognition

Revenue Recognition	12 Months Ended
	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Note 2 - Revenue Recognition Contracts with Customers We have adopted ASC 606, Revenue from Contracts with Customers . We routinely plan on entering into contracts with customers that include general commercial terms and conditions, notification requirements for price increases, shipping terms and in most cases prices for the products and services that we offer. Our performance obligations are established when a customer submits a purchase order notification (in writing, electronically or verbally) for goods and services, and we accept the order. We identify performance obligations as the delivery of the requested product or service in appropriate quantities and to the location specified in the customer’s contract and/or purchase order. We generally recognize revenue upon the satisfaction of these criteria when control of the product or service has been transferred to the customer at which time, we have an unconditional right to receive payment. Our sales and sale prices are final and our prices are not affected by contingent events that could impact the transaction price. Revenues for our SofPulse® product is typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no further performance obligations. In connection with offering products and services provided to the end user by third-party vendors, we review the relationship between us, the vendor and the end user to assess whether revenue should be reported on a gross or net basis. In asserting whether revenue should be reported on a gross or net basis, we consider whether we act as a principal in the transaction and control the goods and services used to fulfill the performance obligation(s) associated with the transaction. During the year ended December 31, 2021, and 2020, we recognized gross revenue of $ 73,105 165,796 Sources of Revenue We have identified the following revenues disaggregated by revenue source: 1. Plastic Surgeons 2. Wound Care Facilities 3. Hospitals 4. Other Physicians As of December 31, 2021, and 2020, the sources of revenue were as follows: Schedule of Source of Revenue Year Ended December 31, 2021 2020 Direct sales- Plastic surgeons, gross 73,105 165,796 Total sources of revenue $ 73,105 $ 165,796 Warranty Our general product warranties do not extend beyond an assurance that the product delivered will be consistent with stated specifications and do not include separate performance obligations. Significant Judgments in the Application of the Guidance in ASC 606 There are no significant judgments associated with the satisfaction of our performance obligations. We generally satisfy performance obligations upon delivery of the product to the customer. This is consistent with the time in which the customer obtains control of the products. Performance obligations are also generally settled quickly after the purchase order acceptance, therefore the value of unsatisfied performance obligations at the end of any reporting period is generally immaterial. We consider variable consideration in establishing the transaction price. Forms of variable consideration applicable to our arrangements include sales returns, rebates, volume-based bonuses, and prompt pay discounts. We use historical information along with an analysis of the expected value to properly calculate and to consider the need to constrain estimates of variable consideration. Such amounts are included as a reduction to revenue from the sale of products in the periods in which the related revenue is recognized and adjusted in future periods as necessary. Practical Expedients Our payment terms for sales direct to distributors, End Users, Hospitals and Doctors are substantially less than the one-year collection period that falls within the practical expedient in determination of whether a significant financing component exists. Effective Date and Transition Disclosures Adoption of the new standards related to revenue recognition did not have a material impact on our consolidated financial statements.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 3- Property and Equipment The following is a summary of equipment, at cost, less accumulated depreciation at December 31, 2021, and 2020: Summary of Property, Plant and Equipment 2021 2020 As of December 31, 2021 2020 Autos $ - $ 64,458 Medical equipment - 13,969 Other equipment - 11,367 Property plant and equipment gross - 89,794 Less accumulated depreciation - 88,214 Property plant and equipment net $ - $ 1,580 Depreciation expense for the years ended December 31, 2021, and 2020 was $ 1,580 4,335

Patents

Patents	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	Note 4 – Patents In December 2017, we acquired from RGN a patent portfolio for $ 4,500,000 The following is a summary of patents less accumulated amortization at December 31, 2021, and 2020: Schedule of Patents 2021 2020 December 31, 2021 2020 Patents $ 4,500,000 $ 4,500,000 Less accumulated amortization 2,587,644 1,940,732 Patents net $ 1,912,356 $ 2,559,268 Amortization expense for the years ended December 31, 2021, and 2020, was $ 646,912 The estimated future amortization expense related to patents as of December 31, 2021, is as follows: Schedule of Estimated Future Amortization Expense Year Ended December 31. Amount 2022 $ 646,910 2023 646,910 2024 618,536 Total $ 1,912,356

Notes payable

Notes payable	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Notes payable	Note 5 - Notes payable Notes Payable During the year ended December 31, 2021, the Company issued eight (8) fixed rate promissory notes totaling $ 950,000 950,000 original terms of twelve months and interest rates of 15% . As of December 31, 2021, the fixed-rate notes had an outstanding balance of $ 1,735,000 , of which $ 785,000 are past maturity. As of December 31, 2020, the fixed-rate notes had an outstanding balance of $ 895,747 , of which $ 25,000 were past maturity. As of December 31, 2021, the Company has 13 fixed rate promissory notes with unrelated parties for total amount of $ 1,735,000 1,000,000 15% During the year ended December 31, 2021, the Company amended the terms of two of its promissory notes to accelerate the conversion feature and amend the conversion price of the instruments. The Company recorded the modification in accordance with ASC 470-50 Debt-Modifications and Extinguishments 58,407 During the year ended December 31, 2021, the Company settled one of its promissory notes by issuing 1,515,152 15 128,000 During the year ended December 31, 2021, the Company converted $ 393,597 100,152 27,461,307 The gross amount of all convertible notes with variable conversion rates outstanding as of December 31, 2021, is $ 4,770,926 4,770,926 Notes payable to a former related party in the aggregate amount of $ 126,100 10 12 16,900 In October 2013, July 2014, October 2014 and August 2015, the Company initiated a series of private placements for up to $ 500,000 25,000 10 624,903 During the year ended December 31, 2020, the Company issued nine fixed rate promissory notes totaling $ 1,485,000 608,117 original terms of two to twelve months and interest rates of 8 15 10 24 301,727 During the year ended December 31, 2020, the Company converted seven (7) previous fixed rate notes into variable rate notes (including the five newly issued fixed rate promissory notes) in an accumulated amount of $ 1,136,000 70 75 100 316,494 525,000 151,496 On May 20, 2020, the Company entered into modification and forbearance agreements (the “agreements”) with three investors as a condition for the execution of the equity line purchase agreement (see note 6), collectively totaling $ 4,397,000 1,080,000 12.5 On July 16, 2020, the Securities and Exchange Commission declared effective the registration statement on Form S-1, for the registration of the shares under the Equity Line Purchase Agreements, which was filed on June 23, 2020, and amended on July 10, 2020. Management reviewed the guidance per ASC 470-60 Troubled debt restructurings Debt-Modifications and Extinguishments Notes payable to a former related party in the aggregate amount of $ 143,000 10 12 22,000 As of December 31, 2021, the Company had notes payable to related parties amounting to $ 126,100 Schedule of Notes Payable 2021 2020 As of December 31, 2021 2020 Notes payable at beginning of period $ 6,835,196 $ 6,874,795 Notes payable issued 950,000 1,364,611 Liquidated damages - 452,095 Notes modification - 25,190 Loan fees added to note payable - 120,389 Settlements on note payable (117,770 ) (697,253 ) Repayments of notes payable in cash (16,900 ) (22,000 ) Less amounts converted to stock (393,596 ) (1,282,631 ) Notes payable at end of period 7,256,930 6,835,196 Less debt discount (75,800 ) (201,157 ) $ 7,181,130 $ 6,634,039 Notes payable issued to former related party $ 126,100 $ 143,000 Notes payable issued to non-related party $ 7,055,030 $ 6,491,039 The maturity dates on the notes payable are as follows: Schedule of Maturity Dates of Notes Payable Twelve months ending, Non-related parties Former Total Past due $ 6,180,830 $ 126,100 $ 6,306,930 December 31, 2022 950,000 - 950,000 Total $ 7,130,830 $ 126,100 $ 7,256,930 Notes payable totaling $ 2,110,450 Acquisition Payable In connection with the Company’s acquisition of IPR in 2012, IPR recorded a $ 155,000 25 During the year ended December 31, 2021, the Company issued 2,505,834 75,175 Effective Interest Rate During the year ended December 31, 2021, and 2020, the Company’s effective interest rate was 12 37

Shareholders_ Deficit

Shareholders’ Deficit	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Shareholders’ Deficit	Note 6 - Shareholders’ Deficit Preferred Stock The Company has authorized 5,000,000 Schedule of Preferred Stock Number of Shares Number of Shares Par Value Liquidation Value Series AA 1,000,000 25,000 $ 0.0010 - Preferred Series B 50,000 600 $ 0.0001 100 Preferred Series C 8,000 738 $ 0.0001 1,000 Preferred Series D 20,000 305 $ 0.0001 1,000 Undesignated 3,922,000 - - - Series AA Preferred Shares On February 22, 2013, the Board of Directors of the Company authorized an amendment to the Company’s Articles of Incorporation, as amended (the “Articles of Incorporation”), in the form of a Certificate of Designation that authorized the issuance of up to one million ( 1,000,000 0.001 Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company 25,000 Series B Convertible Preferred Stock On February 7, 2017, the Company filed a certificate of designation for 50,000 75 three-year 150 100 600 Series C Secured Redeemable Preferred Stock On December 22, 2017, the Company filed a certificate of designation for 8,000 20.00 1,000 the Company filed the amended and restated certificate of designation fort its Series C Secured Redeemable Preferred Stock. The amendment changed the rights of the Series C by (a) removing the requirement to redeem the Series C, (b) removing the obligation to pay dividends on the Series C, (c) Allowing the holders of shares of Series C to convert the stated value of their shares into common stock of the Company at 75% of the closing price of such common stock on the day prior to the conversion. The Series C preferred does not have any rights to vote with the common stock 1,000 Management reviewed the guidance in ASC 470-60 Troubled Debt Restructurings Debt Modifications and Extinguishments 604,000 Management determined the fair value of the new instrument based on the guidance in ASC 820 Fair Value Measurement. Management concluded that the preferred stock should not be classified as a liability per the guidance in ASC 480 Distinguishing Liabilities from Equity even though the conversion would require the issuance of variable number of shares since such obligation is not unconditional. Management classified the Series C in permanent equity as of December 31, 2021, and 2020. During the year ended December 31, 2021, and 2020, the Company converted 25 1,051 1,111,111 2,754,822 738 763 Series D Convertible Preferred Stock On November 11, 2019, the Company filed a certificate of designation for 20,000 0.01 The Series D holders have no voting rights. Upon liquidation, the holder of Series D, shall be entitled to receive an amount equal to the stated value, $ 1,000 During the years ended December 31, 2021, and 2020, 0 50 305 Common Stock Equity Purchase Line Agreement On May 18, 2020, the Company and Cavalry Fund I LP (the “investor”) entered into an Equity Line Purchase Agreement (“ELPA”) pursuant to which the investor committed to purchase, subject to certain restrictions and conditions, up to $ 10,000,000 The Company agreed to issue shares of its common stock (the “commitment shares”) to the investor having a market value of 5% of the commitment ($ 500,000 3,859,630 385,963 3,000,000 The ELPA provides that at any time after the effective date of the registration statement and provided the closing sale price of the common shares on the OTCQB is not below $ 0.01 300,000 400,000 0.25 500,000 0.40 Under the ELPA the Company has the right to submit a regular purchase notice to the investor as often as every business day. The payment for the shares covered by each put notice will generally occur on the day following the put notice. The ELPA contains provisions which allow for the Company to make additional puts beyond the regular purchase amount at greater discounts to the market price of the common stock as forth in the ELPA. The ELPA requires the Company to apply at least 50 During the years ended December 31, 2021, and 2020, pursuant to the execution of the ELPA, the Company issued 0 771,926 97,920 Activity during the year ended December 31, 2021: During the year ended December 31, 2021, the Company issued 27,461,307 1,117,990 During the year ended December 31, 2021, the Company issued 7,868,668 223,000 During the year ended December 31, 2021, the Company issued 7,000,000 126,000 During the year ended December 31, 2021, the Company issued 1,111,111 33,333 During the year ended December 31, 2021, the Company issued 4,020,986 142,424 2,505,834 84,697 During the year ended December 31, 2021, the Company issued 2,500,000 95,000 Activity during the year ended December 31, 2020: During the year ended December 31, 2020, the Company issued 14,557,343 3,339,109 During the year ended December 31, 2020, the Company issued 1,206,398 109,800 During the year ended December 31, 2020, the Company issued 1,234,568 100,000 During the year ended December 31, 2020, the Company issued 1,500,000 165,000 34,690 During the year ended December 31, 2020, the Company issued 58,428 8,152 During the year ended December 31, 2020, the Company issued 2,754,822 1,400,934 During the year ended December 31, 2020, the Company modified the terms of its promissory note with one investor, which extended the maturity date of its promissory note and the issuance of 500,000 55,000 55,000 Troubled Debt Restructurings During the year ended December 31, 2020, in connection with the issuance of a new self-amortization promissory note, the Company issued 355,000 24,140 During the year ended December 31, 2020, the Company issued 409,000 58,855 283,000 525,000 151,496 Debt- Modifications and Extinguishments Stock Options The Company did not issue any stock options during the year ended December 31, 2021. The Company cancelled 2,500,350 During the year ended December 31, 2020, the Company granted stock options to independent contractor exercisable into up to 3,000,000 0.15 2 years The stock options will vest in twelve equal instalments of 250,000 245,900 2,500,000 Share-based compensation expense for the years ended December 31, 2021, and 2020, totaled $ 0 57,400 The weighted average grant date fair value of stock options issued during the year ended December 31, 2020, was $ 0.08 Stock option activities for the years ended December 31, 2021, and 2020, are as follows: Schedule of Stock Options Outstanding Options Weighted Weighted Aggregate Outstanding at December 31, 2019 99,833 $ 27.81 2.02 $ Granted 3,000,000 $ 0.15 1.65 - Cancelled (85,753 ) $ 23.53 0.68 - Exercised - $ - - - Outstanding at December 31, 2020 3,014,080 $ 0.37 1.67 $ - Granted - $ - - - Cancelled (2,500,350 ) $ 0.16 0.65 - Exercised - $ - Outstanding at December 31, 2021 513,730 $ 1.43 0.76 $ - Exercisable at December 31, 2021 513,730 $ 1.43 0.76 $ - The balance of all stock options outstanding as of December 31, 2021, is as follows: Schedule of Share-based Compensation, Shares Authorized Under Stock Option Plans, by Exercise Price Range Outstanding Exercisable Weighted Average Weighted Weighted Range of Remaining Average Average Exercise Number Contractual Exercise Number Exercise Prices Outstanding Life Price Exercisable Price Options $ 54.00 11,750 5.30 $ 54.00 11,750 $ 54.00 $ 11.60 1,980 0.75 $ 11.60 1,980 $ 11.60 $ 0.15 500,000 0.65 $ 0.15 500,000 $ 0.15 513,730 0.76 $ 1.43 513,730 $ 1.43 Warrants During the years ended December 31, 2021, and 2020, the Company did not issue any warrants. A summary of the status of the warrants at December 31, 2021, and changes during the years ended December 31, 2021, and 2020, are presented below: Schedule of Warrants Outstanding Outstanding Warrants Weighted Exercise Price Shares Per Share Outstanding at December 31, 2019 73,486 $ 306.28 Granted - $ - Cancelled (33,920 ) $ 404.55 Exercised (271 ) $ 44.35 Outstanding at December 31, 2020 39,295 $ 200.72 Granted - $ - Cancelled (17,095 ) $ 384.39 Exercised - $ - Outstanding at December 31, 2021 22,200 $ 59.25 Exercisable at December 31, 2021 22,200 $ 59.25 Schedule of Warrants Exercise Price Range Outstanding Exercisable Weighted Average Weighted Weighted Range of Remaining Average Average Exercise Number Contractual Exercise Number Exercise Prices Outstanding Life Price Exercisable Price Warrants $ 14.50 50.00 10,326 0.35 $ 32.64 10,326 $ 32.64 $ 51.00 100.00 10,595 0.29 $ 77.47 10,595 $ 77.47 $ 101.25 239.00 1,203 0.30 $ 114,19 1,203 $ 114.19 $ 266.88 76 0.30 $ 266.88 76 $ 266.88 22,200 0.32 $ 59.25 22,200 $ 59.25

Related Party and former Relate

Related Party and former Related Parties Transactions	12 Months Ended
	Dec. 31, 2021
Related Party Transactions [Abstract]
Related Party and former Related Parties Transactions	Note 7 – Related Party and former Related Parties Transactions One executive officer, one former executive and one former operational manager of the Company have agreed to defer a portion of their compensation until cash flow improves. As of December 31, 2021, and 2020, the balances of their deferred compensation were $ 1,289,625 1,240,575 300,000 250,950 535,000 192,900 From time-to-time officers of the Company advance monies to the Company to cover costs. During the years ended December 31, 2021, and 2020, officers and operational manager advanced $ 13,530 30,074 13,405 23,545 6,529 The balance of short-term advances due to one officer and executive of the Company at December 31, 2021, and 2020 was $ 125 6,529 At December 31, 2021 and 2020, notes payable remain outstanding to the former President of the Company, in the amounts of $ 126,100 143,000 67,787 54,271

Income taxes

Income taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income taxes	Note 8 - Income taxes The Company files income tax returns with the Internal Revenue Service (“IRS”) and various state jurisdictions. For jurisdictions in which tax filings are prepared, the Company is subject to income tax examinations by state tax authorities and federal tax authorities for all tax years. The deferred tax assets are mainly comprised of net loss carryforwards. As of December 31, 2021, and 2020, the Company had approximately $ 29,900,000 and $ 26,900,000 of federal net operating loss carryforwards, respectively, that it can use to offset a certain amount of taxable income in the future. Some of these federal net operating loss carryforwards begin to expire in 2030 . The resulting deferred tax asset is offset by a 100 % valuation allowance due to the uncertainty of its realization. Utilization of these net operating losses could be limited under Section 382 of the Internal Revenue Code of 1986, as amended (the “Code”), and similar state laws based on ownership changes and the value of the Company’s stock. A reconciliation of the provision for income tax expense with the expected income tax computed by applying the federal statutory income tax rate to income before provision for income taxes was as follows for the years ended December 31, 2021, and 2020: Schedule of Effective Income Tax Rate Reconciliation 2021 2020 Income tax computed at federal statutory rate -21.0 % -21.0 % State taxes, net of federal benefit -7.0 % -7.1 % Non-Deductible expenses 1.0 % 15.0 % Change in valuation allowance 27.0 % 13.1 % Total 0.0 % 0.0 % The primary difference between income tax expense attributable to continuing operations and the amount of income tax expense that would result from applying domestic federal statutory rates to income before provision for income taxes relates to the change in the valuation allowance. The Company has adopted the accounting standards that clarify the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements and prescribes a recognition threshold of more likely than not and a measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. In making this assessment, a company must determine whether it is more likely than not that a tax position will be sustained upon examination, based solely on the technical merits of the position, and must assume that the tax position will be examined by taxing authorities. Our policy is to include interest and penalties related to unrecognized tax benefits in income tax expense. Interest and penalties totaled $ 0

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 9 - Commitments and Contingencies Legal matters We were defendants in a case entitled Auctus Fund, LLC v. Endonovo Therapeutics, Inc. et.al 20-cv-11286-PBS 275,250 500,000 The Company is subject to certain legal proceedings, which it considers routine to its business activities. As of December 31, 2021, the Company believes, after consultation with legal counsel, that the ultimate outcome of such legal proceedings, whether individually or in the aggregate, is not likely to have a material adverse effect on the Company’s financial position, results of operations or liquidity.

Concentrations

Concentrations	12 Months Ended
	Dec. 31, 2021
Risks and Uncertainties [Abstract]
Concentrations	Note 10 – Concentrations Sales During the year ended December 31, 2021, we had two significant customers which accounted for 28 25 During the year ended December 31, 2020, we had two significant customers which accounted for 36 20 Supplier We also have a single source for our bioelectric medical devices, which account for 100 Accounts Receivable At December 31, 2021, and 2020, we had two customers which accounted for 67 33

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	N ote 11 - Subsequent Events Subsequent to December 31, 2021, the Company prepared and filed an offering circular on Form 1-A with the Securities and Exchange Commission relating to an offering of up to $ 5,000,000 Subsequent to December 31, 2021, an aggregate of 3,700,000 0 74,000 Subsequent to December 31, 2021, the Company issued 2,428,777 Subsequent to December 31, 2021, the Company executed two convertible notes for a total aggregate principal of $ 200,000 , carrying coupon of 15 %, with due date at the earlier of 30 days after qualification of Form 1-A or November and December 2022, convertible six months from issuance date at a fixed conversion rate. Pursuant to the executed share purchase agreements, the Company issued fully vested 1,400,000 commitment shares. Subsequent to December 31, 2021, the Board of director approved the issuance of 67,500,000 1.2 As a result of these issuances, the total number of common shares outstanding is 149,527,538 , Preferred B shares outstanding is 600 , Preferred C shares outstanding is 763 and Preferred D shares outstanding is 305 .

Nature of Business and Summar_2

Nature of Business and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The consolidated financial statements of the Company include the accounts of ETI, IP Resources International, Inc., Aviva Companies Corporation, and WeHealAnimals, Inc. All significant intercompany accounts and transactions are eliminated in consolidation.
Going Concern	Going Concern These accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for a period following the date of these consolidated financial statements. The Company has recurring net losses, negative cash flows from operations and working capital deficits. The Company has raised approximately $ 1.1
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Critical estimates include the value of shares issued for services, in connection with notes payable agreements, in connection with note extension agreements, and as repayment for outstanding debt, the useful lives of property and equipment, the valuation of the derivative liability, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates.
Cash and cash equivalents	Cash and cash equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Financial instruments that potentially subject us to a concentration of credit risk consist of cash and cash equivalents. Cash is deposited with what we believe are highly credited, quality institutions. The deposited cash may exceed Federal Deposit Insurance Corporation (“FDIC”) insured limits. At December 31, 2021, the Company does not hold any cash in excess of FDIC limits.
Accounts Receivable	Accounts Receivable The Company uses the specific identification method for recording the provision for doubtful accounts, which was $ 0
Property, plant, and equipment	Property, plant, and equipment Property, plant, and equipment are stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range between five seven years
Impairment of Long-lived Assets	Impairment of Long-lived Assets The Company reviews its long-lived assets for impairment whenever events or changes in business circumstances indicate that the carrying amount of assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. If impairment is indicated, the asset is written down to its estimated fair value.
Equity-Based Compensation	Equity-Based Compensation The Company measures equity-based compensation cost at the grant date based on the fair value of the award and recognizes it as expense, net of forfeitures which are recognized as they occur, over the vesting or service period, as applicable, of the stock award using the straight-line method. The Company measured equity-based compensation using the Black-Scholes option valuation model using the following assumptions: Schedule of Measured Stock - Based Compensation For Years Ending December 31, 2021 2020 Expected term - 1.38 Exercise price $ - $ 0.15 Expected volatility - $ 23,110 Expected dividends - None Risk-free interest rate - 0.14 % Forfeitures - None
Income Taxes	Income Taxes The Company records a tax provision for the anticipated tax consequences of its reported results of operations. The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating losses and income tax credit carry-forward. Deferred tax assets and liabilities are measured using the currently enacted tax rates that apply to taxable income in effect for the years in which those tax assets are expected to be realized or settled. The Company records a valuation allowance to reduce deferred tax assets to the amount that is more likely than not to be realized. The Company has adopted ASC Topic 740, which clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. ASC Topic 740 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return, and also provides guidance on derecognition of tax benefits, classification on the balance sheet, interest and penalties, accounting in interim periods, disclosure and transition. The Company has determined that the adoption did not result in the recognition of any liability for unrecognized tax benefits and that there are no unrecognized tax benefits that would, if recognized, affect the Company’s effective tax rate.
Net Loss per Share	Net Loss per Share Basic net loss per share is calculated based on the net loss attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted net loss per common share assumes the conversion of all dilutive securities using the if-converted method and assumes the exercise or vesting of other dilutive securities, such as options, common shares issuable under convertible debt, warrants and restricted stock using the treasury stock method when dilutive.
Research and Development	Research and Development Costs relating to the development of new products are expensed as research and development as incurred in accordance with FASB Accounting Standards Codification (“ASC”) 730-10, Research and Development 0 3,283
Fair Value of Financial Instruments	Fair Value of Financial Instruments Accounting guidance on fair value measurements and disclosures defines fair value, establishes a framework for measuring the fair value of assets and liabilities using a hierarchy system, and defines required disclosures. It clarifies that fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the market in which the reporting entity transacts business. The Company’s balance sheet contains derivative liability that is recorded at fair value on a recurring basis. The three-level valuation hierarchy for disclosure of fair value is as follows: Level 1: uses quoted market prices in active markets for identical assets or liabilities. Level 2: uses observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: uses unobservable inputs that are not corroborated by market data. The fair value of the Company’s recorded derivative liability is determined based on unobservable inputs that are not corroborated by market data, which require a Level 3 classification. A Black-Sholes option valuation model was used to determine the fair value. The Company records derivative liability on the condensed consolidated balance sheets at fair value with changes in fair value recorded in the condensed consolidated statements of operation. The following table presents balances of the liabilities with significant unobservable inputs (Level 3) as of December 31, 2021, and 2020: Schedule of Balances of Liabilities Measured at Fair Value Fair Value Measurements at December 31, 2021 Using Quoted Prices in Significant Significant Identical Observable Unobservable (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 3,442,297 $ 3,442,297 Total $ - $ - $ 3,442,297 $ 3,442,297 Fair Value Measurements at December 31, 2020 Using Quoted Prices in Significant Significant Identical Observable Unobservable (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 4,202,597 $ 4,202,597 Total $ - $ - $ 4,202,597 $ 4,202,597 The following table presents changes of the liabilities with significant unobservable inputs (Level 3) for the years ended December 31, 2021, and 2020: Schedule of Changes in the Liabilities with Significant Unobservable Inputs Derivative Liability Balance December 31, 2019 $ 10,599,690 Issuance of convertible debt 1,244,898 Settlements by debt extinguishment (1,857,356 ) Extinguishment following note exchange (177,422 ) Change in estimated fair value (5,607,213 ) Balance December 31, 2020 $ 4,202,597 Issuance of convertible debt - Settlement by debt Extinguishment (133,386 ) Settlements by debt conversion (585,857 ) Change in estimated fair value (41,057 ) Balance December 31, 2021 $ 3,442,297
Derivative Liability	Derivative Liability The Company issued Variable Debentures during the years ended December 31, 2021, and 2020, which contained variable conversion rates based on unknown future prices of the Company’s common stock. This resulted in a derivative liability. The Company measures the derivative liability using the Black-Scholes option valuation model using the following assumptions: Schedule of Variable Debentures Black-Scholes Valuation Assumptions For Years Ending December 31, 2021 2020 Expected term 1 4 1 6 Exercise price $ 0.01 0.03 $ 0.01 0.76 Expected volatility 177 206 110 249 Expected dividends None None Risk-free interest rate 0.06 0.39 0.03 1.54 Forfeitures None None The assumptions used in determining fair value represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment. As a result, if factors change, including changes in the market value of the Company’s common stock, managements’ assessment or significant fluctuations in the volatility of the trading market for the Company’s common stock, the Company’s fair value estimates could be materially different in the future. The Company computes the fair value of the derivative liability at each reporting period and the change in the fair value is recorded as non-cash expense or non-cash income. The key component in the value of the derivative liability is the Company’s stock price, which is subject to significant fluctuation and is not under its control, and the assessment of volatility. The resulting effect on net loss is therefore subject to significant fluctuation and will continue to be so until the Company’s Variable Debentures, which the convertible feature is associated with, are converted into common stock or paid in full with cash. Assuming all other fair value inputs remain constant, the Company will record non-cash expense when its stock price increases and non-cash income when its stock price decreases.
Preferred Stock	Preferred Stock The Company elects to accrete the difference between the redemption value and carrying value of outstanding preferred stock over the period from the date of issuance to the earliest redemption date using the effective interest method.
Recent Accounting Standard Updates	Recent Accounting Standard Updates In August 2020, the FASB issued ASU No. 2020-06 (“ASU 2020-06”) “Debt-Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity.” ASU 2020-06 simplifies the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models results in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. In addition, ASU 2020-06 amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. The Amendments also affects the diluted EPS calculation for instruments that may be settled in cash or shares and for convertible instruments. The amendments are effective for public entities excluding smaller reporting companies for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods. The Company adopted the new standard update on January 1, 2021, which did not result in a material impact on the Company’s consolidated results of operations, financial position, and cash flows.

Nature of Business and Summar_3

Nature of Business and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Measured Stock - Based Compensation	The Company measured equity-based compensation using the Black-Scholes option valuation model using the following assumptions: Schedule of Measured Stock - Based Compensation For Years Ending December 31, 2021 2020 Expected term - 1.38 Exercise price $ - $ 0.15 Expected volatility - $ 23,110 Expected dividends - None Risk-free interest rate - 0.14 % Forfeitures - None
Schedule of Balances of Liabilities Measured at Fair Value	The following table presents balances of the liabilities with significant unobservable inputs (Level 3) as of December 31, 2021, and 2020: Schedule of Balances of Liabilities Measured at Fair Value Fair Value Measurements at December 31, 2021 Using Quoted Prices in Significant Significant Identical Observable Unobservable (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 3,442,297 $ 3,442,297 Total $ - $ - $ 3,442,297 $ 3,442,297 Fair Value Measurements at December 31, 2020 Using Quoted Prices in Significant Significant Identical Observable Unobservable (Level 1) (Level 2) (Level 3) Total Derivative liability $ - $ - $ 4,202,597 $ 4,202,597 Total $ - $ - $ 4,202,597 $ 4,202,597
Schedule of Changes in the Liabilities with Significant Unobservable Inputs	The following table presents changes of the liabilities with significant unobservable inputs (Level 3) for the years ended December 31, 2021, and 2020: Schedule of Changes in the Liabilities with Significant Unobservable Inputs Derivative Liability Balance December 31, 2019 $ 10,599,690 Issuance of convertible debt 1,244,898 Settlements by debt extinguishment (1,857,356 ) Extinguishment following note exchange (177,422 ) Change in estimated fair value (5,607,213 ) Balance December 31, 2020 $ 4,202,597 Issuance of convertible debt - Settlement by debt Extinguishment (133,386 ) Settlements by debt conversion (585,857 ) Change in estimated fair value (41,057 ) Balance December 31, 2021 $ 3,442,297
Schedule of Variable Debentures Black-Scholes Valuation Assumptions	The Company issued Variable Debentures during the years ended December 31, 2021, and 2020, which contained variable conversion rates based on unknown future prices of the Company’s common stock. This resulted in a derivative liability. The Company measures the derivative liability using the Black-Scholes option valuation model using the following assumptions: Schedule of Variable Debentures Black-Scholes Valuation Assumptions For Years Ending December 31, 2021 2020 Expected term 1 4 1 6 Exercise price $ 0.01 0.03 $ 0.01 0.76 Expected volatility 177 206 110 249 Expected dividends None None Risk-free interest rate 0.06 0.39 0.03 1.54 Forfeitures None None

Revenue Recognition (Tables)

Revenue Recognition (Tables)	12 Months Ended
	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Schedule of Source of Revenue	As of December 31, 2021, and 2020, the sources of revenue were as follows: Schedule of Source of Revenue Year Ended December 31, 2021 2020 Direct sales- Plastic surgeons, gross 73,105 165,796 Total sources of revenue $ 73,105 $ 165,796

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Summary of Property, Plant and Equipment	The following is a summary of equipment, at cost, less accumulated depreciation at December 31, 2021, and 2020: Summary of Property, Plant and Equipment 2021 2020 As of December 31, 2021 2020 Autos $ - $ 64,458 Medical equipment - 13,969 Other equipment - 11,367 Property plant and equipment gross - 89,794 Less accumulated depreciation - 88,214 Property plant and equipment net $ - $ 1,580

Patents (Tables)

Patents (Tables)	12 Months Ended
	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Patents	The following is a summary of patents less accumulated amortization at December 31, 2021, and 2020: Schedule of Patents 2021 2020 December 31, 2021 2020 Patents $ 4,500,000 $ 4,500,000 Less accumulated amortization 2,587,644 1,940,732 Patents net $ 1,912,356 $ 2,559,268
Schedule of Estimated Future Amortization Expense	The estimated future amortization expense related to patents as of December 31, 2021, is as follows: Schedule of Estimated Future Amortization Expense Year Ended December 31. Amount 2022 $ 646,910 2023 646,910 2024 618,536 Total $ 1,912,356

Notes payable (Tables)

Notes payable (Tables)	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Schedule of Notes Payable	Schedule of Notes Payable 2021 2020 As of December 31, 2021 2020 Notes payable at beginning of period $ 6,835,196 $ 6,874,795 Notes payable issued 950,000 1,364,611 Liquidated damages - 452,095 Notes modification - 25,190 Loan fees added to note payable - 120,389 Settlements on note payable (117,770 ) (697,253 ) Repayments of notes payable in cash (16,900 ) (22,000 ) Less amounts converted to stock (393,596 ) (1,282,631 ) Notes payable at end of period 7,256,930 6,835,196 Less debt discount (75,800 ) (201,157 ) $ 7,181,130 $ 6,634,039 Notes payable issued to former related party $ 126,100 $ 143,000 Notes payable issued to non-related party $ 7,055,030 $ 6,491,039
Schedule of Maturity Dates of Notes Payable	The maturity dates on the notes payable are as follows: Schedule of Maturity Dates of Notes Payable Twelve months ending, Non-related parties Former Total Past due $ 6,180,830 $ 126,100 $ 6,306,930 December 31, 2022 950,000 - 950,000 Total $ 7,130,830 $ 126,100 $ 7,256,930

Shareholders_ Deficit (Tables)

Shareholders’ Deficit (Tables)	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Schedule of Preferred Stock	The Company has authorized 5,000,000 Schedule of Preferred Stock Number of Shares Number of Shares Par Value Liquidation Value Series AA 1,000,000 25,000 $ 0.0010 - Preferred Series B 50,000 600 $ 0.0001 100 Preferred Series C 8,000 738 $ 0.0001 1,000 Preferred Series D 20,000 305 $ 0.0001 1,000 Undesignated 3,922,000 - - -
Schedule of Stock Options Outstanding	Stock option activities for the years ended December 31, 2021, and 2020, are as follows: Schedule of Stock Options Outstanding Options Weighted Weighted Aggregate Outstanding at December 31, 2019 99,833 $ 27.81 2.02 $ Granted 3,000,000 $ 0.15 1.65 - Cancelled (85,753 ) $ 23.53 0.68 - Exercised - $ - - - Outstanding at December 31, 2020 3,014,080 $ 0.37 1.67 $ - Granted - $ - - - Cancelled (2,500,350 ) $ 0.16 0.65 - Exercised - $ - Outstanding at December 31, 2021 513,730 $ 1.43 0.76 $ - Exercisable at December 31, 2021 513,730 $ 1.43 0.76 $ -
Schedule of Share-based Compensation, Shares Authorized Under Stock Option Plans, by Exercise Price Range	The balance of all stock options outstanding as of December 31, 2021, is as follows: Schedule of Share-based Compensation, Shares Authorized Under Stock Option Plans, by Exercise Price Range Outstanding Exercisable Weighted Average Weighted Weighted Range of Remaining Average Average Exercise Number Contractual Exercise Number Exercise Prices Outstanding Life Price Exercisable Price Options $ 54.00 11,750 5.30 $ 54.00 11,750 $ 54.00 $ 11.60 1,980 0.75 $ 11.60 1,980 $ 11.60 $ 0.15 500,000 0.65 $ 0.15 500,000 $ 0.15 513,730 0.76 $ 1.43 513,730 $ 1.43
Schedule of Warrants Outstanding	A summary of the status of the warrants at December 31, 2021, and changes during the years ended December 31, 2021, and 2020, are presented below: Schedule of Warrants Outstanding Outstanding Warrants Weighted Exercise Price Shares Per Share Outstanding at December 31, 2019 73,486 $ 306.28 Granted - $ - Cancelled (33,920 ) $ 404.55 Exercised (271 ) $ 44.35 Outstanding at December 31, 2020 39,295 $ 200.72 Granted - $ - Cancelled (17,095 ) $ 384.39 Exercised - $ - Outstanding at December 31, 2021 22,200 $ 59.25 Exercisable at December 31, 2021 22,200 $ 59.25
Schedule of Warrants Exercise Price Range	Schedule of Warrants Exercise Price Range Outstanding Exercisable Weighted Average Weighted Weighted Range of Remaining Average Average Exercise Number Contractual Exercise Number Exercise Prices Outstanding Life Price Exercisable Price Warrants $ 14.50 50.00 10,326 0.35 $ 32.64 10,326 $ 32.64 $ 51.00 100.00 10,595 0.29 $ 77.47 10,595 $ 77.47 $ 101.25 239.00 1,203 0.30 $ 114,19 1,203 $ 114.19 $ 266.88 76 0.30 $ 266.88 76 $ 266.88 22,200 0.32 $ 59.25 22,200 $ 59.25

Income taxes (Tables)

Income taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation	A reconciliation of the provision for income tax expense with the expected income tax computed by applying the federal statutory income tax rate to income before provision for income taxes was as follows for the years ended December 31, 2021, and 2020: Schedule of Effective Income Tax Rate Reconciliation 2021 2020 Income tax computed at federal statutory rate -21.0 % -21.0 % State taxes, net of federal benefit -7.0 % -7.1 % Non-Deductible expenses 1.0 % 15.0 % Change in valuation allowance 27.0 % 13.1 % Total 0.0 % 0.0 %

Schedule of Measured Stock - Ba

Schedule of Measured Stock - Based Compensation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Expected term		1 year 4 months 17 days
Exercise price		$ 0.15
Expected volatility		$ 23,110
Expected dividends		0.00%
Risk-free interest rate		0.14%
Forfeitures

Schedule of Balances of Liabili

Schedule of Balances of Liabilities Measured at Fair Value (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Defined Benefit Plan Disclosure [Line Items]
Derivative liability	$ 3,442,297	$ 4,202,597
Total	3,442,297	4,202,597	$ 10,599,690
Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Derivative liability
Total
Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Derivative liability
Total
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Derivative liability	3,442,297	4,202,597
Total	$ 3,442,297	$ 4,202,597

Schedule of Changes in the Liab

Schedule of Changes in the Liabilities with Significant Unobservable Inputs (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Derivative liability, beginning balance	$ 4,202,597	$ 10,599,690
Issuance of convertible debt		1,244,898
Settlements by debt extinguishment	(133,386)	(1,857,356)
Extinguishment following note exchange		(177,422)
Change in estimated fair value	(41,057)	(5,607,213)
Settlements by debt extinguishment	(585,857)
Derivative liability, ending balance	$ 3,442,297	$ 4,202,597

Schedule of Variable Debentures

Schedule of Variable Debentures Black-Scholes Valuation Assumptions (Details)	12 Months Ended
	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Forfeitures
Measurement Input, Expected Term [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term	1 month	1 month
Measurement Input, Expected Term [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Expected term	4 months	6 months
Measurement Input, Exercise Price [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability measurement	0.01	0.01
Measurement Input, Exercise Price [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability measurement	0.03	0.76
Measurement Input, Option Volatility [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability measurement	177	110
Measurement Input, Option Volatility [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability measurement	206	249
Measurement Input, Expected Dividend Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability measurement	0	0
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability measurement	0.06	0.03
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative liability measurement	0.39	1.54

Nature of Business and Summar_4

Nature of Business and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Restructuring Cost and Reserve [Line Items]
Debt and equity financing	$ 1,100,000
Provision for doubtful accounts	0	$ 0
Research and development expenses	$ 0	$ 3,283
Minimum [Member]
Restructuring Cost and Reserve [Line Items]
Property plant and equipment, estimated useful lives	5 years
Maximum [Member]
Restructuring Cost and Reserve [Line Items]
Property plant and equipment, estimated useful lives	7 years
Hanover Portfolio Acquisitions Inc [Member]
Restructuring Cost and Reserve [Line Items]
Acquisitions description	On January 22, 2014, Hanover Portfolio Acquisitions, Inc. (the “Company”) received written consents in lieu of a meeting of stockholders from holders of a majority of the shares of Common Stock representing in excess of 50% of the total issued and outstanding voting power of the Company approving an amendment to the Company’s Certificate of Incorporation to change the name of the Company from “Hanover Portfolio Acquisitions, Inc.” to “Endonovo Therapeutics, Inc.” The name change was affected pursuant to a Certificate of Amendment (the “Certificate of Amendment”), filed with the Secretary of State of Delaware on January 24, 2014
Common stock, voting rights	Common Stock representing in excess of 50% of the total issued and outstanding voting power

Schedule of Source of Revenue (

Schedule of Source of Revenue (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disaggregation of Revenue [Line Items]
Total sources of revenue	$ 73,105	$ 165,796
Direct Sales Medical Care Providers Gross [Member]
Disaggregation of Revenue [Line Items]
Total sources of revenue	$ 73,105	$ 165,796

Revenue Recognition (Details Na

Revenue Recognition (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenue from Contract with Customer [Abstract]
Recognized net revenues	$ 73,105	$ 165,796

Summary of Property, Plant and

Summary of Property, Plant and Equipment (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property plant and equipment gross		$ 89,794
Less accumulated depreciation		88,214
Property plant and equipment net		1,580
Autos [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment gross		64,458
Medical Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment gross		13,969
Other Equipment [Member]
Property, Plant and Equipment [Line Items]
Property plant and equipment gross		$ 11,367

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 1,580	$ 4,335

Schedule of Patents (Details)

Schedule of Patents (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 4,500,000	$ 4,500,000
Less accumulated amortization	2,587,644	1,940,732
Patents net	$ 1,912,356	$ 2,559,268

Schedule of Estimated Future Am

Schedule of Estimated Future Amortization Expense (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
2022	$ 646,910
2023	646,910
2024	618,536
Patents net	$ 1,912,356	$ 2,559,268

Patents (Details Narrative)

Patents (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2021	Dec. 31, 2020
Amortization expense		$ 646,912	$ 646,912
Rio Grande Neurosciences Inc [Member]
Acquisition of patents	$ 4,500,000

Schedule of Notes Payable (Deta

Schedule of Notes Payable (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Debt Disclosure [Abstract]
Notes payable at beginning of period	$ 6,835,196	$ 6,874,795
Notes payable issued	950,000	1,364,611
Liquidated damages		452,095
Notes modification		25,190
Loan fees added to note payable		120,389
Settlements on note payable	(117,770)	(697,253)
Repayments of notes payable in cash	(16,900)	(22,000)
Less amounts converted to stock	(393,596)	(1,282,631)
Notes payable at end of period	7,256,930	6,835,196
Debt discount	(75,800)	(201,157)
Notes payable net	7,181,130	6,634,039
Notes payable issued to a former related party	126,100	143,000
Notes payable issued to non-related parties	$ 7,055,030	$ 6,491,039

Schedule of Maturity Dates of N

Schedule of Maturity Dates of Notes Payable (Details)	Dec. 31, 2021USD ($)
Defined Benefit Plan Disclosure [Line Items]
Past due	$ 6,306,930
December 31, 2022	950,000
Total	7,256,930
Non Related Parties [Member]
Defined Benefit Plan Disclosure [Line Items]
Past due	6,180,830
December 31, 2022	950,000
Total	7,130,830
Former Related Party [Member]
Defined Benefit Plan Disclosure [Line Items]
Past due	126,100
December 31, 2022
Total	$ 126,100

Notes payable (Details Narrativ

Notes payable (Details Narrative) - USD ($)	1 Months Ended				12 Months Ended
	Aug. 31, 2015	Oct. 31, 2014	Jul. 31, 2014	Oct. 31, 2013	Dec. 31, 2021	Dec. 31, 2020	May 20, 2020	Dec. 31, 2019
Short-term Debt [Line Items]
Notes payable					$ 7,256,930	$ 6,835,196		$ 6,874,795
Proceeds from issuance of note payable					950,000	608,117
Gain from debt extinguishment					22,162	(555,430)
Debt conversion, stock issued					393,597
Accrued interest					$ 100,152
Debt conversion, stock issued					27,461,307
Note payable related parties					$ 126,100	143,000
Note payable outstanding					$ 7,055,030	$ 6,491,039
Shares as extingusihment					2,505,834
Debt instrument periodic payment					$ 75,175
Debt effective interest rate					12.00%	37.00%
Intellectual Property Rights [Member]
Short-term Debt [Line Items]
Long-term acquisition payable for costs not paid at closing					$ 155,000
Percentage of proceeds from any private placement or gross profits					25.00%
Rio Grande Neurosciences Inc [Member] | Intellectual Property [Member]
Short-term Debt [Line Items]
Notes payable					$ 2,110,450
Private Placement [Member]
Short-term Debt [Line Items]
Proceeds from issuance of note payable	$ 25,000	$ 25,000	$ 25,000	$ 25,000
Debt instrument, interest rate	10.00%	10.00%	10.00%	10.00%
Debt instrument face amount	$ 500,000	$ 500,000	$ 500,000	$ 500,000
Note payable outstanding					624,903	$ 624,903
Three Investors [Member] | Forbearance Agreements [Member]
Short-term Debt [Line Items]
Accrued interest							$ 1,080,000
Debt instrument face amount							$ 4,397,000
Debt instrument premium percentage							12.50%
Eight Fixed Rate Promissory Notes [Member]
Short-term Debt [Line Items]
Notes payable					950,000
Proceeds from issuance of note payable					$ 950,000
Debt instrument description					original terms of twelve months and interest rates of 15%. The holders of the promissory notes can convert the outstanding unpaid principal and accrued interest at a fixed conversion rate, subject to standard anti-dilution features
Debt instrument, interest rate					15.00%
Fixed Rated Notes [Member]
Short-term Debt [Line Items]
Notes payable					$ 1,735,000	895,747
Fixed Rated Notes [Member] | Past Maturity [Member]
Short-term Debt [Line Items]
Notes payable					785,000	25,000
Thirteen Fixed Rate Promissory Notes [Member] | Unrelated Parties [Member]
Short-term Debt [Line Items]
Notes payable					1,735,000
Nine Fixed Rate Promissory Notes [Member]
Short-term Debt [Line Items]
Notes payable						1,485,000
Proceeds from issuance of note payable						$ 608,117
Debt instrument description						original terms of two to twelve months and interest rates of 8% to 15%. If the notes are not paid at maturity, the fixed rate promissory notes bear a default interest of 10% to 24%
Derivative liability for embedded conversion feature						$ 301,727
Nine Fixed Rate Promissory Notes [Member] | Minimum [Member]
Short-term Debt [Line Items]
Debt effective interest rate						10.00%
Nine Fixed Rate Promissory Notes [Member] | Maximum [Member]
Short-term Debt [Line Items]
Debt instrument, interest rate						15.00%
Debt effective interest rate						24.00%
Nine Fixed Rate Promissory Notes [Member] | Unrelated Parties [Member]
Short-term Debt [Line Items]
Notes payable					$ 1,000,000
Realized profit, percentage					15.00%
Two Promissory Notes [Member] | Gain (Loss) on Derivative Instruments [Member]
Short-term Debt [Line Items]
Gain from debt extinguishment					$ 58,407
One Promissory Notes [Member]
Short-term Debt [Line Items]
Gain from debt extinguishment					$ 128,000
Number of shares issued for debt					1,515,152
Percentage of debt provision					15.00%
Convertible Notes [Member]
Short-term Debt [Line Items]
Convertible Debt					$ 4,770,926
Convertible Notes [Member] | Past Maturity [Member]
Short-term Debt [Line Items]
Convertible Debt					4,770,926
Notes Payable [Member] | Former Related Party [Member]
Short-term Debt [Line Items]
Note payable related parties					126,100	$ 143,000
Principal payment of debt					$ 16,900	$ 22,000
Notes Payable [Member] | Former Related Party [Member] | Minimum [Member]
Short-term Debt [Line Items]
Debt instrument, interest rate					10.00%	10.00%
Notes Payable [Member] | Former Related Party [Member] | Maximum [Member]
Short-term Debt [Line Items]
Debt instrument, interest rate					12.00%	12.00%
Notes Payable [Member] | Related Party [Member]
Short-term Debt [Line Items]
Note payable related parties					$ 126,100
Nine Promissory Notes [Member] | Minimum [Member]
Short-term Debt [Line Items]
Debt instrument, interest rate						8.00%
Previous Fixed Rate Notes [Member] | Note Holder [Member]
Short-term Debt [Line Items]
Debt instrument face amount						$ 1,136,000
Four of Variable Rate Notes [Member] | Note Holder [Member] | Minimum [Member]
Short-term Debt [Line Items]
Debt instrument, interest rate						70.00%
Four of Variable Rate Notes [Member] | Note Holder [Member] | Maximum [Member]
Short-term Debt [Line Items]
Debt instrument, interest rate						75.00%
Three of Variable Rate Notes [Member] | Note Holder [Member]
Short-term Debt [Line Items]
Debt instrument, interest rate						100.00%
Variable Notes [Member]
Short-term Debt [Line Items]
Debt instrument face amount						$ 316,494
Promissory Notes [Member]
Short-term Debt [Line Items]
Gain from debt extinguishment						151,496
Covertible debt current						$ 525,000
Shares as extingusihment					7,868,668

Schedule of Preferred Stock (De

Schedule of Preferred Stock (Details)	Dec. 31, 2021USD ($)$ / sharesshares
Series AA [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares authorized	1,000,000
Number of shares outstanding	25,000
Par value | $ / shares	$ 0.0010
Liquidation value | $
Preferred Series B [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares authorized	50,000
Number of shares outstanding	600
Par value | $ / shares	$ 0.0001
Liquidation value | $	$ 100
Preferred Series C [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares authorized	8,000
Number of shares outstanding	738
Par value | $ / shares	$ 0.0001
Liquidation value | $	$ 1,000
Preferred Series D [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares authorized	20,000
Number of shares outstanding	305
Par value | $ / shares	$ 0.0001
Liquidation value | $	$ 1,000
Undesignated [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares authorized	3,922,000
Number of shares outstanding
Par value | $ / shares
Liquidation value | $

Schedule of Stock Options Outst

Schedule of Stock Options Outstanding (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregated intrinsic value, outstanding, granted
Aggregated intrinsic value, exercisable ending
Aggregated intrinsic value, exercisable ending
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option outstanding, beginning balance	3,014,080	99,833
Weighted average exercise price, beginning balance	$ 0.37	$ 27.81
Weighted average remaining contractual term (years), outstanding beginning		2 years 7 days
Aggregated intrinsic value, outstanding beginning balance
Stock option outstanding, granted		3,000,000
Weighted average exercise price, granted		$ 0.15
Weighted average remaining contractual term (years), granted		1 year 7 months 24 days
Aggregated intrinsic value, outstanding, granted
Stock option outstanding, cancelled	(2,500,350)	(85,753)
Weighted average exercise price, cancelled	$ 0.16	$ 23.53
Weighted average remaining contractual term (years), cancelled	7 months 24 days	8 months 4 days
Aggregated intrinsic value, outstanding, cancelled
Stock option outstanding, exercised
Weighted average exercise price, exercised
Weighted average remaining contractual term (years), exercised
Aggregated intrinsic value, outstanding beginning balance
Weighted average remaining contractual term (years), outstanding beginning	1 year 8 months 1 day
Stock option outstanding, exercised
Stock option outstanding, ending balance	513,730	3,014,080
Weighted average exercise price, ending balance	$ 1.43	$ 0.37
Weighted average remaining contractual term (years), outstanding ending balance	9 months 3 days
Stock option outstanding, exercisable ending balance	513,730
Weighted average exercise price, ending balance	$ 1.43
Weighted average remaining contractual term (years), outstanding ending balance	9 months 3 days

Schedule of Share-based Compens

Schedule of Share-based Compensation, Shares Authorized Under Stock Option Plans, by Exercise Price Range (Details) - Stock Options [Member]	12 Months Ended
	Dec. 31, 2021$ / sharesshares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of outstanding | shares	513,730
Weighted average remaining contractual life	9 months 3 days
Weighted average exercise price	$ 1.43
Number of exercisable | shares	513,730
Weighted average exercise price exercisable	$ 1.43
Price Range One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Range of exercise prices	$ 54
Number of outstanding | shares	11,750
Weighted average remaining contractual life	5 years 3 months 18 days
Weighted average exercise price	$ 54
Number of exercisable | shares	11,750
Weighted average exercise price exercisable	$ 54
Price Range Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Range of exercise prices	$ 11.60
Number of outstanding | shares	1,980
Weighted average remaining contractual life	9 months
Weighted average exercise price	$ 11.60
Number of exercisable | shares	1,980
Weighted average exercise price exercisable	$ 11.60
Price Range Three [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Range of exercise prices	$ 0.15
Number of outstanding | shares	500,000
Weighted average remaining contractual life	7 months 24 days
Weighted average exercise price	$ 0.15
Number of exercisable | shares	500,000
Weighted average exercise price exercisable	$ 0.15

Schedule of Warrants Outstandin

Schedule of Warrants Outstanding (Details) - Warrant [Member] - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares outstanding, beginning balance	39,295	73,486
Weighted average exercise price per shares outstanding, beginning balance	$ 200.72	$ 306.28
Shares, granted
Weighted-average exercise price, granted
Shares, cancelled	(17,095)	(33,920)
Weighted average exercise price, cancelled	$ 384.39	$ 404.55
Shares, exercised		(271)
Weighted-average exercise price, exercised		$ 44.35
Shares outstanding, ending balance	22,200	39,295
Weighted-average exercise price, exercisable ending balance	$ 59.25	$ 200.72
Shares outstanding, ending balance	22,200
Weighted-average exercise price, exercisable ending balance	59.25

Schedule of Warrants Exercise P

Schedule of Warrants Exercise Price Range (Details) - Warrant [Member] - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of warrants outstanding	22,200	39,295	73,486
Weighted average remaining contractual life	3 months 25 days
Weighted average exercise price	$ 59.25
Number of warrants exercisable	22,200
Weighted average exerice price	59.25
Price Range One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Range of exercise prices, lower limit	$ 14.50
Range of exercise prices. upper limit	$ 50
Number of warrants outstanding	10,326
Weighted average remaining contractual life	4 months 6 days
Weighted average exercise price	$ 32.64
Number of warrants exercisable	10,326
Weighted average exerice price	32.64
Price Range Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Range of exercise prices, lower limit	$ 51
Range of exercise prices. upper limit	$ 100
Number of warrants outstanding	10,595
Weighted average remaining contractual life	3 months 14 days
Weighted average exercise price	$ 77.47
Number of warrants exercisable	10,595
Weighted average exerice price	77.47
Price Range Three [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Range of exercise prices, lower limit	$ 101.25
Range of exercise prices. upper limit	$ 239
Number of warrants outstanding	1,203
Weighted average remaining contractual life	3 months 18 days
Weighted average exercise price	$ 114.19
Number of warrants exercisable	1,203
Weighted average exerice price	114.19
Price Range Four [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Range of exercise prices. upper limit	$ 266.88
Number of warrants outstanding	76
Weighted average remaining contractual life	3 months 18 days
Weighted average exercise price	$ 266.88
Number of warrants exercisable	76
Weighted average exerice price	266.88

Shareholders_ Deficit (Details

Shareholders’ Deficit (Details Narrative) - USD ($)	May 18, 2020	Jan. 29, 2020	Dec. 22, 2017	Feb. 07, 2017	Feb. 22, 2013	Dec. 31, 2021	Dec. 31, 2020	Nov. 11, 2019
Class of Stock [Line Items]
Stated value dividend							0.00%
Gain on debt extinguishment						$ 22,162	$ (555,430)
Issuance of common stock, value						$ 126,000	$ 100,000
Issuance of common stock, shares						2,505,834
Common stock price per share						$ 0.0001	$ 0.0001
Shares issued for conversion of notes payable and accrued interest, shares						27,461,307
Shares issued for conversion of notes payable and accrued interest						$ 1,117,990	$ 3,339,109
Common stock issued for services							109,800
Restricted stock value shares issued net of tax
Number of inducement on restricted shares, shares							355,000
Inducement on restricted shares							$ 24,140
Share-based compensation expenses						$ 0	57,400
Weighted average grant date fair value of stock options						$ 0.08
Restricted Stock [Member]
Class of Stock [Line Items]
Gain on debt extinguishment							$ 55,000
Restricted stock shares issued net of tax							500,000
Restricted stock value shares issued net of tax							$ 55,000
Equity Option [Member]
Class of Stock [Line Items]
Stock option forfeited						2,500,350	2,500,000
Share based compensation arrangement by share options outstanding intrinsic value							$ 245,900
One Investor [Member]
Class of Stock [Line Items]
Gain on debt extinguishment							151,496
Issuance of common stock, value							$ 58,855
Issuance of common stock, shares							409,000
Convertible note principal amount							$ 283,000
Convertible debt							$ 525,000
Independent Contractor [Member]
Class of Stock [Line Items]
Stock options exercise price per share							$ 0.15
Stock option term							2 years
Stock option vested							250,000
Promissory Notes [Member]
Class of Stock [Line Items]
Gain on debt extinguishment							$ 151,496
Issuance of common stock, value						$ 223,000
Issuance of common stock, shares						7,868,668
Settlement of Debt [Member]
Class of Stock [Line Items]
Issuance of common stock, value						$ 142,424
Issuance of common stock, shares						4,020,986
Minimum [Member] | Independent Contractor [Member]
Class of Stock [Line Items]
Stock option to officers							3,000,000
Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Issuance of common stock, value						$ 126,000	$ 100,000
Issuance of common stock, shares						7,000,000	1,234,568
Conversion of Series C Preferred Stock [Member]
Class of Stock [Line Items]
Issuance of common stock, value						$ 33,333	$ 1,400,934
Issuance of common stock, shares						1,111,111	2,754,822
Consulting Agreement [Member]
Class of Stock [Line Items]
Issuance of common stock, value						$ 95,000
Issuance of common stock, shares						2,500,000
Conversion of Series C Stock [Member]
Class of Stock [Line Items]
Issuance of common stock, shares							1,206,398
Common stock issued for services							$ 109,800
Cavalry Fund I LP [Member]
Class of Stock [Line Items]
Issuance of common stock, value							$ 3,339,109
Issuance of common stock, shares							14,557,343
Cavalry Fund I LP [Member] | Equity Line Purchase Agreement [Member]
Class of Stock [Line Items]
Purchase obligation	$ 10,000,000
Issuance of common stock, shares	300,000
Commitment shares to be issued pro-rata	$ 3,000,000
Commitment share description	The ELPA provides that at any time after the effective date of the registration statement and provided the closing sale price of the common shares on the OTCQB is not below $0.01, from time to time on any business day selected by the Company (the “Purchase Date”), the Company shall have the right, but not the obligation, to direct the investor to buy up to 300,000 shares of the common stock (the “regular purchase amount”) at a purchase price equal to the lower of: (i) the lowest applicable sales price on the date of the put and (ii) 85% of the arithmetic average of the 3 lowest closing prices for the common stock during the 10 consecutive trading days ending on the trading day immediately preceding such put date. The regular purchase amount may be increased as follows: to up to 400,000 shares of common stock if the closing price of the common shares is not below $0.25 per share and up to 500,000 shares if the closing price is not below $0.40 per share
Proceeds of puts to payment	50.00%
Cavalry Fund I LP [Member] | Equity Line Purchase Agreement [Member] | Minimum [Member]
Class of Stock [Line Items]
Common stock price per share	$ 0.01
Cavalry Fund I LP [Member] | Equity Line Purchase Agreement [Member] | Share-based Payment Arrangement, Tranche Two [Member] | Maximum [Member]
Class of Stock [Line Items]
Issuance of common stock, shares	400,000
Common stock price per share	$ 0.25
Cavalry Fund I LP [Member] | Equity Line Purchase Agreement [Member] | Share-based Payment Arrangement, Tranche Three [Member] | Maximum [Member]
Class of Stock [Line Items]
Issuance of common stock, shares	500,000
Common stock price per share	$ 0.40
Former Related Party [Member]
Class of Stock [Line Items]
Issuance of common stock, value						$ 84,697
Issuance of common stock, shares						2,505,834
Common Stock [Member]
Class of Stock [Line Items]
Conversion of stock, shares converted						1,111,111	2,754,822
Issuance of common stock, value						$ 700	$ 123
Issuance of common stock, shares						7,000,000	1,234,568
Shares issued for conversion of notes payable and accrued interest, shares						27,461,307	14,557,343
Shares issued for conversion of notes payable and accrued interest						$ 2,746	$ 1,456
Common stock issued for services							$ 120
Restricted stock shares issued net of tax							58,428
Restricted stock value shares issued net of tax							$ 6
Common Stock [Member] | Holders [Member]
Class of Stock [Line Items]
Issuance of common stock, value							$ 8,152
Issuance of common stock, shares							58,428
Commitment Shares [Member] | Cavalry Fund I LP [Member] | Equity Line Purchase Agreement [Member] | Share-based Payment Arrangement, Tranche One [Member]
Class of Stock [Line Items]
Issuance of common stock, value	$ 500,000
Commitment Shares [Member] | Cavalry Fund I LP [Member] | Equity Line Purchase Agreement [Member] | Share-based Payment Arrangement, Tranche Two [Member]
Class of Stock [Line Items]
Issuance of common stock, shares	3,859,630
Commitment Shares [Member] | Cavalry Fund I LP [Member] | Equity Line Purchase Agreement [Member] | Share-based Payment Arrangement, Tranche Three [Member]
Class of Stock [Line Items]
Issuance of common stock, shares	385,963
Stock Options [Member]
Class of Stock [Line Items]
Issuance of common stock, value							$ 165,000
Issuance of common stock, shares							1,500,000
Stock issued for reverse stock splits							34,690
Series AA Preferred Stock [Member]
Class of Stock [Line Items]
Number of shares outstanding					1,000,000
Preferred stock, par value					$ 0.001
Preferred stock voting rights					Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company
Preferred stock, shares outstanding						25,000	25,000
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Number of shares outstanding				50,000
Preferred stock, shares outstanding						600	600
Stated value dividend				75.00%
Warrants term				three-year
Share exercise price				150.00%
Liquidation value of preferred stock, per share				$ 100
Series C Convertible Redeemable Preferred Stock [Member]
Class of Stock [Line Items]
Number of shares outstanding			8,000
Liquidation value of preferred stock, per share						$ 1,000
Preferred stock, dividend per share			$ 20
Shares issued, price per share			$ 1,000
Change in rights due to amendment and restated certificate, description		the Company filed the amended and restated certificate of designation fort its Series C Secured Redeemable Preferred Stock. The amendment changed the rights of the Series C by (a) removing the requirement to redeem the Series C, (b) removing the obligation to pay dividends on the Series C, (c) Allowing the holders of shares of Series C to convert the stated value of their shares into common stock of the Company at 75% of the closing price of such common stock on the day prior to the conversion. The Series C preferred does not have any rights to vote with the common stock
Gain on debt extinguishment							$ 604,000
Conversion of stock, shares converted						25	1,051
Convertible preferred stock shares outstanding						738	763
Series D Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Number of shares outstanding						20,000	20,000	20,000
Preferred stock, par value						$ 0.0001	$ 0.0001
Preferred stock, shares outstanding						305	305
Liquidation value of preferred stock, per share						$ 1,000
Convertible preferred stock shares outstanding						305	305
Conversion price								0.01%
Convertible preferred stock shares issued						0	50
Common Stock [Member]
Class of Stock [Line Items]
Issuance of common stock, value						$ 97,920
Issuance of common stock, shares						0	771,926

Related Party and former Rela_2

Related Party and former Related Parties Transactions (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Related Party Transaction [Line Items]
Repayment of related party debt	$ 16,900	$ 22,000
Notes payable - related parties	126,100	143,000
Accrued interest	2,528,459	1,904,136
Executive Officer Former Executive and Former Operational Manager [Member]
Related Party Transaction [Line Items]
Deferred compensation	1,289,625	1,240,575
Accrual of deferred compensation	300,000	535,000
Cash repayments of deferred compensation	250,950	192,900
Officers and Operational Manager [Member]
Related Party Transaction [Line Items]
Related party advances	13,530	30,074
Repayment of related party debt	13,405	23,545
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Due to officer	6,529
One Officer and Executive [Member]
Related Party Transaction [Line Items]
Due to officer	125	6,529
Former President [Member]
Related Party Transaction [Line Items]
Notes payable - related parties	126,100	143,000
Accrued interest	$ 67,787	$ 54,271

Schedule of Effective Income Ta

Schedule of Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income tax computed at federal statutory rate	(21.00%)	(21.00%)
State taxes, net of federal benefit	(7.00%)	(7.10%)
Non-Deductible expenses	1.00%	15.00%
Change in valuation allowance	27.00%	13.10%
Total	0.00%	0.00%

Income taxes (Details Narrative

Income taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount	$ 29,900,000	$ 26,900,000
Income Tax Examination, Description	begin to expire in 2030
Effective Income Tax Rate Reconciliation, Other Adjustments, Percent	100.00%
Interest and penalties	$ 0	$ 0

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - Auctus Fund, LLC [Member]	1 Months Ended
	Aug. 31, 2019USD ($)
Minimum [Member]
Loss Contingencies [Line Items]
Loss Contingency, Damages Sought, Value	$ 500,000
Note [Member]
Loss Contingencies [Line Items]
Debt Instrument, Face Amount	$ 275,250

Concentrations (Details Narrati

Concentrations (Details Narrative) - Revenue Benchmark [Member] - Customer Concentration Risk [Member]	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Concentration Risk [Line Items]
Concentration risk, percentage	100.00%
Customer One [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	28.00%	36.00%
Customer Two [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	25.00%	20.00%
Accounts Receivable One [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	67.00%
Accounts Receivable Two [Member]
Concentration Risk [Line Items]
Concentration risk, percentage		33.00%

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
	Apr. 08, 2022	Dec. 31, 2021	Dec. 31, 2020	Feb. 15, 2022
Subsequent Event [Line Items]
Debt conversion, shares issued		27,461,307
Debt principal amount		$ 393,597
Interest payable		$ 100,152
Issuance of common stock, shares		2,505,834
Approved for issuance,shares	67,500,000
Approved for issuance,value	$ 1,200,000
Common stock, shares outstanding		74,498,761	24,536,689
Series B Preferred Stock [Member]
Subsequent Event [Line Items]
Preferred stock, shares outstanding		600	600
Subsequent Event [Member]
Subsequent Event [Line Items]
Debt Instrument, Face Amount	$ 200,000
Debt Instrument, Interest Rate, Stated Percentage	15.00%
Debt Instrument, Term	30 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares	1,400,000
Subsequent Event [Member] | Series B Preferred Stock [Member]
Subsequent Event [Line Items]
Preferred stock, shares outstanding				600
Subsequent Event [Member] | Series C Preferred Stock [Member]
Subsequent Event [Line Items]
Preferred stock, shares outstanding				763
Subsequent Event [Member] | Series D Preferred Stock [Member]
Subsequent Event [Line Items]
Preferred stock, shares outstanding				305
Subsequent Event [Member] | Debt Settlement Agreement [Member]
Subsequent Event [Line Items]
Issuance of common stock, shares	2,428,777
Subsequent Event [Member] | Restricted Stock [Member]
Subsequent Event [Line Items]
Debt conversion, shares issued	3,700,000
Debt principal amount	$ 0
Interest payable	74,000
Common Stock [Member]
Subsequent Event [Line Items]
Debt conversion, shares issued		27,461,307	14,557,343
Issuance of common stock, shares		7,000,000	1,234,568
Common Stock [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Proceeds from offerings	$ 5,000,000
Common stock, shares outstanding				149,527,538